Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality, and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs approved for PH are considerable, driven by premium pricing and the high propensity for polypharmacy. Although this market has become congested, commercial interest in PH remains high. The great need for more-efficacious and disease-modifying agents, as well as approved treatment options for unserved populations, fuels the opportunity in this space.
Questions answered
- Novel agents such as United Therapeutics’ ralinepag, Merck & Co.’s sotatercept, Liquidia’s Yutrepia, and United Therapeutics / MannKind’s Tyvaso DPI are in late-phase development for the treatment of PH. What do interviewed thought leaders say about the advantages and disadvantages of these therapies? How will the launch of these agents affect prescribing decisions?
- Generic formulations have launched for several key branded therapies in recent years. How have these launches impacted prescribing patterns? How have/will generic launches impact the uptake of entrenched and emerging branded therapies?
- Great unmet need exists for the treatment of PH WHO groups 2, and 5. What are the other key unmet needs in PH? How likely are these unmet needs to be fulfilled within the forecast period?
- Pulmonary arterial hypertension patients are normally prescribed PDE-5 inhibitors and/or ERAs as first-line therapy. What are the treatment guidelines for later lines of therapy? How do these vary between geographical regions?
Content highlights
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Key drugs covered: Uptravi, Orenitram, Adempas, Opsumit, Adcirca, Tracleer, Revatio, Letairis / Volibris, Remodulin, Flolan, Veletri, Tyvaso, Ventavis, Beraprost, ralinepag, Yutrepia, Tyvaso DPI, sotatercept, macitentan / tadalafil FDC.
Key companies mentioned: Actelion, United Therapeutics, Bayer HealthCare, GlaxoSmithKline, Gilead Sciences, Pfizer, MannKind Corporation, Merck & Co., Liquidia Technologies.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Pulmonary Hypertension - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Pulmonary hypertension u2013 key findings u2013 November 2022
- Key updates
- Q4 2022
- December 2022
- November 2022
- October 2022
- Q3 2022
- August 2022
- July 2022
- Q2 2022
- June 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2022
- Market outlook
- Key findings
- Market share of drug classes for pulmonary arterial hypertension: 2021
- Market share of drug classes for pulmonary arterial hypertension: 2031
- Pulmonary hypertension SWOT analysis
- Market drivers and constraints
- What factors are driving the market for pulmonary hypertension?
- What factors are constraining the market for pulmonary hypertension?
- Overall pulmonary arterial hypertension sales and patient share by drug class: 2021-2031
- Overall pulmonary arterial hypertension market by functional class: 2021-2031
- Overall pulmonary arterial hypertension sales by region: 2021-2031
- Overall pulmonary arterial hypertension patient share by brand / generic: 2021-2031
- Overall inoperable chronic thromboembolic pulmonary hypertension sales and patient share: 2021-2031
- Overall pulmonary hypertension-interstitial lung disease sales and patient share: 2021-2031
- Drug-class-specific trends
- Pulmonary arterial hypertension sales and patient share for endothelin receptor antagonists: 2021-2031
- Pulmonary arterial hypertension sales and patient share for phosphodiesterase-5 inhibitors: 2021-2031
- Oral prostacyclins
- Inhaled prostacyclins
- Parenteral prostacyclins
- Pulmonary arterial hypertension sales and patient share for oral prostacyclin analogues: 2021-2031
- Pulmonary arterial hypertension sales and patient share for inhaled prostacyclin analogues: 2021-2031
- Pulmonary arterial hypertension sales and patient share for parenteral prostacyclin analogues: 2021-2031
- Pulmonary arterial hypertension sales and patient share for soluble guanylate cyclase stimulators: 2021-2031
- Pulmonary arterial hypertension sales and patient share for TGF-u03b2 ligand trap: 2021-2031
- Pulmonary arterial hypertension sales and patient share for endothelin receptor antagonist / phosphodiesterase-5 inhibitor fixed-dose combination: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions - pulmonary arterial hypertension
- Market forecast dashboard - pulmonary arterial hypertension
- Market forecast assumptions - chronic thromboembolic pulmonary hypertension
- Market forecast dashboard - chronic thromboembolic pulmonary hypertension
- Market forecast assumptions - pulmonary hypertension-interstitial lung disease
- Market forecast dashboard - pulmonary hypertension-interstitial lung disease
- Etiology and pathophysiology
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods and sources used
- Disease definition
- Methods and sources used
- Diagnosed prevalent cases of pulmonary arterial hypertension in the major pharmaceutical markets, 2021-2031
- Disease definition
- Methods and sources used
- Diagnosed prevalent cases of pulmonary hypertension due to left heart disease in the major pharmaceutical markets, 2021-2031
- Disease definition
- Methods and sources used
- Diagnosed prevalent cases of pulmonary hypertension due to lung disease and/or hypoxemia in the major pharmaceutical markets, 2021-2031
- Disease definition
- Methods and sources used
- Diagnosed prevalent cases of chronic thromboembolic pulmonary hypertension in the major pharmaceutical markets, 2021-2031
- Methods and sources used
- Diagnosed prevalent cases of pulmonary hypertension that have received surgical treatment in the major pharmaceutical markets, 2021-2031
- Disease definition
- Methods and sources used
- Diagnosed prevalent cases of pulmonary hypertension due to miscellaneous causes in the major pharmaceutical markets, 2021-2031
- Disease definition
- Methods and sources used
- Diagnosed prevalent cases of pulmonary arterial hypertension by NYHA functional class in the major pharmaceutical markets, 2021-2031
- Disease definition
- Methods and sources used
- Disease definition
- Methods and sources used
- Diagnosed prevalence of pulmonary hypertension due to lung disease by subgroup in the major pharmaceutical markets, 2021-2031
- Sources used for drug-treated cases of pulmonary hypertension
- Drug-treated cases of PAH
- Drug-treated cases of inoperable CTEPH
- Drug-treated cases of PH-ILD
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for pulmonary hypertension
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for pulmonary hypertension
- Current treatments used for pulmonary hypertension
- Market events impacting the use of key current therapies for pulmonary hypertension market
- Advantages and disadvantages of bosentan
- Advantages and disadvantages of ambrisentan
- Advantages and disadvantages of Opsumit
- Key results from select clinical trials investigating Opsumit for the treatment of pulmonary hypertension
- Key ongoing clinical trials of Opsumit in the treatment of pulmonary hypertension
- Expert insight: endothelin receptor antagonists
- Advantages and disadvantages of sildenafil
- Advantages and disadvantages of tadalafil
- Expert insight: PDE-5 inhibitors
- Advantages and disadvantages of parenteral epoprostenol
- Advantages and disadvantages of parenteral treprostinil
- Expert insight: parenteral prostacyclins
- Advantages and disadvantages of Tyvaso
- Key ongoing clinical trials of Tyvaso in the treatment of pulmonary hypertension
- Advantages and disadvantages of Ventavis
- Expert insight: inhaled prostacyclin therapy
- Advantages and disadvantages of Orenitram
- Advantages and disadvantages of Uptravi
- Key results from select clinical trials investigating Opsumit for the treatment of pulmonary hypertension
- Key ongoing clinical trials of Uptravi in the treatment of pulmonary hypertension
- Advantages and disadvantages of beraprost and beraprost MR
- Expert insight: oral prostacyclins
- Advantages and disadvantages of Adempas
- Key ongoing clinical trials of Adempas in the treatment of pulmonary hypertension
- Key results from clinical trials of Adempas in the treatment of pulmonary hypertension
- Expert insight: Adempas
- Medical practice
- Overview
- Factors influencing drug selection in pulmonary hypertension
- Treatment decision tree for pulmonary arterial hypertension: United States
- Treatment decision tree for pulmonary arterial hypertension: Europe
- Treatment decision tree for pulmonary arterial hypertension: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in pulmonary hypertension
- Top unmet needs in pulmonary hypertension: current and future attainment
- Expert insight: unmet need in pulmonary hypertension
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for pulmonary hypertension
- Estimated launch dates of key emerging therapies for the treatment of pulmonary hypertension
- Key results from select clinical trials investigating ralinepag for the treatment of pulmonary hypertension
- Key ongoing clinical trials of ralinepag in the treatment of pulmonary hypertension
- Ralinepag clinical development
- Expert insight: ralinepag
- Expectations for launch and sales opportunity for ralinepag in pulmonary hypertension
- Key results from select clinical trials investigating dry powder-inhaled treprostinil for the treatment of pulmonary hypertension
- Dry powder-inhaled treprostinil clinical development
- Expert insight: dry powder-inhaled treprostinil
- Expectations for launch and sales opportunity for dry powder-inhaled treprostinil in pulmonary hypertension
- Key results from select clinical trials investigating sotatercept for the treatment of pulmonary hypertension
- Key ongoing clinical trials of sotatercept in the treatment of pulmonary hypertension
- Sotatercept clinical development
- Expert insight: sotatercept
- Expectations for launch and sales opportunity of sotatercept in pulmonary hypertension
- Macitentan / tadalafil fixed-dose combination profile
- Key ongoing clinical trials of macitentan / tadalafil fixed-dose combination in the treatment of pulmonary hypertension
- Macitentan / tadalafil fixed-dose combination clinical development
- Expert insight: macitentan / tadalafil fixed-dose combination
- Expectations for launch and sales opportunity of macitentan / tadalafil fixed-dose combination in pulmonary hypertension
- Early-phase pipeline analysis
- Select compounds in early-phase / Phase II development for pulmonary hypertension
- Key discontinuations
- Key findings
- Access and reimbursement
- Region-specific reimbursement practices
- Key market access considerations for pulmonary hypertension therapies: United States
- Key market access considerations for pulmonary hypertension therapies: EU5
- Key market access considerations for pulmonary hypertension therapies: Japan
- Region-specific reimbursement practices
- Appendix
- Pulmonary hypertension bibliography
- Key findings
Sayani Datta, M.Sc., Lead Healthcare Research & Data Analyst – Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders. Sayani’s primary areas of focus are nonalcoholic steatohepatitis (NASH) and pulmonary hypertension (PH). Previously, she was an associate consultant with IQVIA. She has worked on various types of custom and syndicated research projects in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, commercial opportunity assessments, and market tracking and intelligence. She is an M.Sc. in biotechnology from the University of Leeds, where she gained exposure to life sciences research and development working as a postgraduate research intern.
Ullas Ulahannan, MPH., Epidemiologist, Epidemiology. Before joining Clarivate, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. His qualifications include a master’s degree in public health from Manipal University, Manipal, and a bachelor’s degree in nursing from Rajiv Gandhi University of Health Sciences, Bangalore